Harmony Biosciences Holdings announces public offering
| GYRE Stock | 9.53 0.05 0.53% |
About 54% of Gyre Therapeutics' investor base is interested to short. The analysis of the overall investor sentiment regarding Gyre Therapeutics suggests that many traders are impartial. The current market sentiment, together with Gyre Therapeutics' historical and current headlines, can help investors time the market. In addition, many technical investors use Gyre Therapeutics stock news signals to limit their universe of possible portfolio assets.
Harmony Biosciences Holdings announces public offering of up to 8M shares, with J.P.
Read at seekingalpha.com
 |
Gyre Therapeutics Fundamental Analysis
We analyze Gyre Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Gyre Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Gyre Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Total Asset
Total Asset Comparative Analysis
Gyre Therapeutics is currently under evaluation in total asset category among its peers. Total Asset is everything that a business owns. It is the sum of current and long-term assets owned by a firm at a given time. These assets are listed on a balance sheet and typically valued based on their purchasing prices, not the current market value.
Gyre Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Gyre Therapeutics stock to make a market-neutral strategy. Peer analysis of Gyre Therapeutics could also be used in its relative valuation, which is a method of valuing Gyre Therapeutics by comparing valuation metrics with similar companies.
Peers
Gyre Therapeutics Related Equities
| SONO | Sonos | 6.00 | ||||
| SHAK | Shake Shack | 1.48 | ||||
| JDDSF | JD Sports | 0.00 | ||||
| DLTTF | Dalata Hotel | 0.00 | ||||
| UBSFF | Ubisoft Entertainment | 0.95 | ||||
| PLAY | Dave Busters | 5.61 |
Complementary Tools for Gyre Stock analysis
When running Gyre Therapeutics' price analysis, check to measure Gyre Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Gyre Therapeutics is operating at the current time. Most of Gyre Therapeutics' value examination focuses on studying past and present price action to predict the probability of Gyre Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Gyre Therapeutics' price. Additionally, you may evaluate how the addition of Gyre Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Commodity Directory Find actively traded commodities issued by global exchanges |